Danielle van Wijk

BYON4228 is a pan-allelic antagonistic SIRPα antibody that potentiates destruction of antibody-opsonized tumor cells and lacks binding to SIRPγ on T cells

R. Ubink, T. K. van den Berg, M. Paradé, 2023, Journal for ImmunoTherapy of Cancer.

Preclinical Profile of BYON3521 Predicts an Effective and Safe MET Antibody–Drug Conjugate

R. Ubink, Kim Berentsen, P. Groothuis, 2023, Molecular cancer therapeutics.